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UNBLOCKED FUTURE:  
WHY GENE PATENTS WON’T HINDER  
WHOLE GENOME SEQUENCING AND  
PERSONALIZED MEDICINE 
W. Nicholson Price II∗ 
ABSTRACT 
 
Whole-genome sequencing has been hailed as the crucial next step in 
personalized medicine. It has also been described as likely violating hun-
dreds—if not thousands—of pre-existing patents on individual genes. 
These claims of patent infringement, however, are usually made without 
detailed analysis. Instead of stating that infringement definitely occurs, or 
in what circumstances it occurs, the discussion of whole-genome sequenc-
ing mentions that some claims may be typically infringed, but some may 
be invalid, and leaves the matter there. This Article seeks to provide a 
detailed analysis of the ways that whole-genome sequencing may infringe 
extant gene patents, focusing on the common basic structure of most such 
patents. In particular, the sequencing step itself may infringe the composi-
tion-of-matter claims of isolated DNA molecules in only a very few gene 
patents, with novel nanopore sequencing technology appearing to bypass 
infringement altogether. Gene patents often also include methods claims 
for comparing the personal sequence with a reference sequence for diag-
nostic purposes; these claims are much more likely to be infringed by any 
plausible whole-genome sequencing effort, but appear to fall into a two-
class trap whereby comparison-only methods claims are vulnerable to 
section 101 patentable subject matter challenges and determination-and-
comparison methods can be relatively easily avoided by having different 
entities perform the sequencing and analysis steps. The Article concludes 
with a brief analysis of policy considerations for whole-genome sequencing 
and suggestions for moving forward. 
 
 ∗  Visiting Scholar, UCSF/UC Hastings Consortium on Law, Science and Health Policy, UC 
Hastings College of the Law. Columbia Law School, J.D. 2011. Columbia Graduate School of 
Arts and Sciences, Department of Biology, Ph.D. 2010. The author wishes to thank Hal Edgar, 
Bob Cook-Deegan, Jaime King, Henry Lebowitz, Jerry Sobel, and Ana Bračič for their very 
helpful comments and feedback. 
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Personalized medicine has been hailed as the next great evolution 
in health care.1 People differ, and the diseases they have differ as well. 
Personalized medicine aims to identify and use those variations to im-
prove medical care.2 Genetic differences can influence which diseases an 
 
 1 C. Li, Personalized Medicine—The Promised Land: Are We There Yet?, 79 CLINICAL 
GENETICS 403–12 (2011). 
 2 See generally Edward Abrahams & Mike Silver, The Case for Personalized Medicine, 3 J. 
DIABETES SCI. & TECH. 680 (2009); Suraksha Agrawal & Faisal Khan, Human Genetic Variation 
and Personalized Medicine, 51 INDIAN J. PHYSIOLOGY & PHARMACOLOGY (2007); Geoffrey S. 
Ginsburg & Jeanette J. McCarthy, Personalized Medicine: Revolutionizing Drug Discovery and 
Patient Care, 19 TRENDS IN BIOTECHNOLOGY 491 (2001); Geoffrey S. Ginsburg & Huntington 
F. Willard, Genomic and Personalized Medicine: Foundations and Applications, 154 TRANSLA-
TIONAL RES. 277 (2009); Kyung-Won Hong & Bermseok Oh, Overview of Personalized Medicine 
in the Disease Genomic Era, 43 BMB REP. 643 (2010); Yuqiu Jiang & Mu Wang, Personalized 
Medicine in Oncology: Tailoring the Right Drug to the Right Patient, 4 BIOMARKERS MED. 523 
(2010); Laviero Mancinelli et al., Pharmacogenomics: The Promise of Personalized Medicine, 2 
AAPS J. 29 (2002); Robert Roberts, Personalized Medicine: A Reality Within This Decade, 1 J. 
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individual experiences, differences in the course of those diseases, and 
how the individual responds to treatment. The paradigmatic field of 
personalized medicine is pharmacogenomics, which focuses on deter-
mining how people react differently to drugs based on their genetic dif-
ferences.3 As the directors of the FDA and NIH jointly put it, personal-
ized medicine is about “the best ways to develop new therapies and 
optimize prescribing by steering patients to the right drug at the right 
dose at the right time.”4 Many factors play into the growth of personal-
ized medicine: identifying the right genetic markers to study, clinically 
demonstrating relationships between genetic variants and drug respons-
es; and limiting side effects of these targeted therapies.5 
For truly personalized medicine, widespread availability of whole-
genome sequencing is a crucial step.6 Whole-genome sequencing 
(WGS) differs from genetic testing as commonly performed today in the 
same way that the detailed satellite map of a parcel differs from a sur-
veyor’s listing of identifiable landmarks. Current genetic testing is usual-
ly for a specific gene—for instance, the BRCA1 gene which relates to a 
predisposition for breast cancer—and determines which variant of the 
gene the patient has at that particular locus. Even the companies that 
today offer generalized genetic services—companies like Navigenics7 or 
23andMe8—actually only examine a relatively small number of specific 
loci on the genome of the patient, correlating the results at those loci 
with already-known genetic variations.9 WGS, on the other hand, is the 
technique of actually determining the entire sequence—base by base—of 
the full genome of a patient, resulting in a string of around six billion 
 
CARDIOVASCULAR TRANSLATIONAL RES. 11 (2008); Gregory E. Simon & Roy H. Perlis, Person-
alized Medicine for Depression: Can We Match Patients with Treatments?, 167 AM. J. PSYCHIA-
TRY 1445 (2010); Michael J. Wagner, Pharmacogenetics and Personal Genomes, 6 PERSONAL-
IZED MED. 643 (2009); Gary E. Marchant, Personalized Medicine and the Law, ARIZ. ATT’Y, Oct. 
2007, at 12. 
 3 See, e.g.,Mancinelli et al., supra note 2; Liewei Wang et al., Genomics and Drug Response, 
364 NEW ENG. J. MED. 1144 (2011); Teresa Kelton, Pharmacogenomics: The Rediscovery of the 
Concept of Tailored Drug Therapy and Personalized Medicine, HEALTH LAW., Jan. 2007, at 1. 
 4 Margaret A. Hamburg & Francis S. Collins, The Path to Personalized Medicine, 363 NEW 
ENG. J. MED. 301, 301 (2010). 
 5 Id. 
 6 See, e.g., Boris Pasche & Devin Absher, Whole-Genome Sequencing: A Step Closer to 
Personalized Medicine, 305 JAMA 1596, 1596–97 (2011). But see Wylie Burke & Bruce M. Psaty, 
Personalized Medicine in the Era of Genomics, 298 JAMA 1682, 1682–84 (2007) (arguing that 
genomics will make only moderate contributions to personalized medicine). 
 7 NAVIGENICS, http://www.navigenics.com (last visited Feb. 15, 2012). 
 8 23ANDME, https://www.23andme.com (last visited Feb. 15, 2012). 
 9 Navigenics and 23andMe both offer genotyping services, where genetic markers are 
identified, rather than full sequencing services. See FAQs, NAVIGENICS, http://www.navigenics.
com/visitor/what_we_offer/faqs (last visited Feb. 15, 2012); Using Your Personal DNA Test, 
23ANDME, https://www.23andme.com/howitworks (last visited Feb. 15, 2012). 
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As, Cs, Gs, and Ts, representing the adenine, cytosine, guanine, and 
thymine bases actually present in the individual’s chromosomes.10 
The additional information provided by WGS facilitates personal-
ized medicine in two ways. First, widespread WGS increases the availa-
bility of the information needed to determine how drugs work with dif-
ferent genetic variations.11 Genomic association studies correlate drug 
reactions to genetic variations. For instance, individuals with a certain 
gene might have a higher predisposition to breast cancer,12 while those 
with another gene might be hypersensitive to a particular drug.13 WGS 
allows those correlations to be made at a more nuanced level, and as 
WGS becomes more prevalent, such studies will have larger potential 
pools of data on which to draw. Second, widespread availability of WGS 
allows individuals being treated to know and use their own detailed 
genetic information.14 This, in combination with the correlations just 
discussed, can be used to select or tailor treatment according to the pa-
tient’s own genetic characteristics.15 
The enterprise of WGS, however, faces substantial barriers, not on-
ly technical and financial, but also based on intellectual property con-
straints. Many thousands of patents have been issued covering individu-
al human genes.16 Each of these could potentially be infringed by a WGS 
technique, which, by definition, involves looking not only at specific 
places in the human genome, but also at every base and every gene—
and, consequently, at every gene which is covered by any human gene 
patent. (Hereinafter, unless otherwise specified, all gene patents are as-
sumed to be for human genes, though some descriptions, such as the 
format of common claims, may apply to non-human gene patents as 
well.) Descriptions of WGS and personalized medicine often mention 
this problem, but usually as a relatively unspecific problem of “likely 
infringement” which must be addressed by broad policy changes.17 This 
 
 10 Pauline C. Ng & Ewen F. Kirkness, Whole Genome Sequencing, 628 METHODS MOLECU-
LAR BIOLOGY 215, 216 (2010). 
 11 See, e.g., Wang et al., supra note 3, at 1144–51. 
 12 See, e.g., Francine Durocher et al., Mutation Analysis of the BRCA1 Gene in 23 Families 
with Cases of Cancer of the Breast, Ovary, and Multiple Other Sites, 33 J. MED. GENETICS 814 
(1996). 
 13 See, e.g., Mark McCormack et al., HLA-A*3101 and Carbamazepine-Induced Hypersensi-
tivity Reactions in Europeans, 364 NEW ENG. J. MED. 1134 (2011). 
 14 See, e.g., Pasche & Absher, supra note 6. 
 15 Abrahams & Silver, supra note 2; Mancinelli et al., supra note 2; Wagner, supra note 2. 
 16 The most recent comprehensive study of human gene patents found that in 2005, patents 
covered over 20% of human genes, or 4382 genes out of around 23,000. (Because of continuing 
research, the number of sequences classified as “genes” fluctuates somewhat.) Kyle Jensen & 
Fiona Murray, Intellectual Property Landscape of the Human Genome, 310 SCIENCE 239, 239 
(2005). 
 17 See, e.g., SEC’Y’S ADVISORY COMM. ON GENETICS, HEALTH & SOC’Y, DEP’T OF HEALTH & 
HUMAN SERVS., GENE PATENTS AND LICENSING PRACTICES AND THEIR IMPACT ON PATIENT 
ACCESS TO GENETIC TESTS 17 (2010) (hereinafter SACGHS REPORT), available at 
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understandable assumption appears to be based on three factors: First, 
analysis of WGS infringement is complex; thousands of gene patents 
exist, and any truly exhaustive analysis is daunting in scope. Second, 
that WGS infringes gene patents makes intuitive sense on either a super-
ficial or slightly deeper level: on a superficial level, gene patents cover 
genes, and WGS requires looking at and using genes, so infringement 
seems likely; on a slightly deeper level, gene patents claim isolated DNA 
molecules, and WGS does involve determining the sequence of genes 
through creating and using isolated DNA molecules. Third and finally, 
older generations of DNA sequencing may in fact have infringed cur-
rent gene patents. Whether or not WGS infringes individual gene pa-
tents, however, is far from clear: in Association for Molecular Pathology 
v. U.S. Patent and Trademark Office (AMP I (district) or AMP II (appel-
late)) the high-profile litigation over Myriad Genetics’ BRCA1/2 breast 
cancer predisposition gene patents, attorneys disagreed vigorously about 
whether WGS would infringe Myriad’s patents.18 Though the majority 
expressed no opinion on the subject, which was not a litigated issue, 
Judge Bryson claimed in his dissent that “some of Myriad’s challenged 
composition claims effectively preempt any attempt to sequence the 
BRCA genes, including whole-genome sequencing.”19 
 
http://oba.od.nih.gov/oba/sacghs/reports/SACGHS_patents_report_2010.pdf (finding that 
required licensing of many gene patents will impede whole-genome sequencing); Subhashini 
Chandrasekharan & Robert Cook-Deegan, Gene Patents and Personalized Medicine—What Lies 
Ahead?, 1 GENOME MED. 92, 94 (2009) (“Our preliminary analysis suggests that microarray-
based methods of genetic analysis and gene variants, and a fortiori full-genome sequencing 
could arguably infringe on some patent claims.”); Courtney C. Scala, Making the Jump from 
Gene Pools to Patent Pools: How Patent Pools Can Facilitate the Development of Phar-
macogenomics, 41 CONN. L. REV. 1631, 1661 (2008) (stating that pharmacogenomics requires 
addressing the gene “patent thicket”); Robert Cook-Deegan, Lecture at Columbia Univ. Med. 
Ctr.: The Topsy-Turvy World of Gene Patents (Nov. 18, 2010) (slides on file with author); 
David P. Lentini & Stephen A. Bent, Intellectual Property: Patents and Genomic Medicine, 
BIO·ITWORLD (Nov. 19, 2004), http://www.bio-itworld.com/archive/111904/si_gm.html. 
 18 Ass’n for Molecular Pathology v. USPTO (AMP II), 653 F.3d 1329 (Fed. Cir. 2011). At 
oral argument before the Federal Circuit, Judge Bryson asked Gregory Castanias, Myriad’s 
counsel, about this issue: “To me, at least, it is an important question as to how preclusive your 
patent—and any other patent on any particular gene—would be if, in effect, you have to get 
100, 200 or 1,000 licenses before you can sequence the genome of an individual.” Oral Argu-
ment at 11:53–12:13, AMP II, 653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-1406), available at 
http://oralarguments.cafc.uscourts.gov/Audiomp3/2010-1406.mp3. Mr. Castanias, while initial-
ly stating, “I’m not sure that my client has formed a view on that,” went on to argue that it 
would depend on the technology involved, but that sequencing either very short (thirty-two 
nucleotide fragments) or very long (whole chromosomes) segments would not violate the 
patents, as he read them. Id. at 12:13–18, 1:08:33–47 (based on the definition of “isolation” in 
the patents). Christopher Hansen, on the other hand, arguing for the ACLU on behalf of the 
plaintiffs, argued that WGS would violate Myriad’s patents, particularly its sequence-
comparison methods patents. Id. at 34:00–08. 
 19 AMP II, 653 F.3d at 119–20 (Bryson, J., concurring in part and dissenting in part). Judge 
Bryson went on to cite the SACGHS report, supra note 17, at 49–62, referencing the “thicket of 
[gene] patents” that would require WGS firms to license “thousands of patents from many 
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This Article seeks to clarify the infringement landscape with re-
spect to WGS, and concludes that most, if not all isolated DNA gene 
patents are likely not infringed by WGS. In brief response20 to the three 
factors listed immediately above: first, gene patents can be grouped into 
patterns, so that a reliable analysis does not require exhaustive canvass-
ing; second, a close look at the specific mechanics of WGS shows that 
first- and second-level superficial analyses deceptively suggest infringe-
ment; and third, WGS technology has moved beyond older sequencing 
techniques in ways that matter for infringement analysis. 
For these reasons, isolated DNA gene patents are likely not in-
fringed by WGS. Infringement is especially unlikely for a nascent tech-
nology, nanopore sequencing, which appears more likely to actually 
fulfill the requirements of true personalized medicine. Other gene pa-
tent claims cover not the isolated genes themselves, but instead the pro-
cess of comparing genetic sequences for use in a diagnosis. These claims 
are more likely infringed by personalized medicine and WGS, since that 
comparison is at the heart of personalized medicine, but are either likely 
invalid or relatively easily worked around by separating the steps of the 
method to be completed by different actors. 
As an important caveat, this Article will not argue the question of 
whether patents claiming isolated genes should themselves be valid. 
This issue has been the subject of much scholarly debate,21 but has long 
been considered settled by the U.S. Patent and Trademark Office 
(USPTO)22 and isolated gene patents have recently been upheld as pa-
tentable subject matter by the U.S. Court of Appeals for the Federal Cir-
 
different licensors.” AMP II, 653 F.3d at 138 (Bryson, J., concurring in part and dissenting in 
part). 
 20 Although these three factors may most reasonably explain why there is a casual assump-
tion that WGS infringes many gene patents, they are not the most productive framework for 
actually analyzing current infringement. Therefore, the infringement analysis will not be 
grouped according to these three factors; however, where relevant, their applicability will be 
mentioned. 
 21 See generally Lori B. Andrews & Jordan Paradise, Gene Patents: The Need for Bioethics 
Scrutiny and Legal Change, 5 YALE J. HEALTH POL’Y L. & ETHICS 403 (2005); Daniel J. Kevles & 
Ari Berkowitz, The Gene Patenting Controversy: A Convergence of Law, Economic Interests, and 
Ethics, 67 BROOK. L. REV. 233 (2001); Patricia A. Lacy, Gene Patenting: Universal Heritage vs. 
Reward for Human Effort, 77 OR. L. REV. 783 (1998); Barbara Looney, Should Genes Be Patent-
ed? The Gene Patenting Controversy: Legal, Ethical, and Policy Foundations of an International 
Agreement, 26 L. & POL’Y INT’L BUS. 231 (1994); John F. Merz, Disease Gene Patents: Overcom-
ing Unethical Constraints on Clinical Laboratory Medicine, 45 CLINICAL CHEMISTRY 324 (1999); 
John F. Merz et al., Diagnostic Testing Fails the Test, 415 NATURE 577 (2002); David B. Resnik, 
The Morality of Human Gene Patents, 7 KENNEDY INST. ETHICS J. 43 (1997). 
 22 See, e.g., Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5, 2001) (describing 
guidelines for evaluating “gene patents”). For an evaluation of the guidelines, see Anna E. 
Morrison, The U.S. PTO’s New Utility Guidelines: Will They Be Enough to Secure Gene Patent 
Rights?, 1 J. MARSHALL REV. INTELL. PROP. L. 142 (2001); Theresa M. Summers, The Scope of 
Utility in the Twenty-First Century: New Guidance for Gene-Related Patents, 91 GEO. L.J. 475 
(2002). 
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cuit (Federal Circuit) in Association for Molecular Pathology v. USPTO.23 
Therefore, despite the possibility of an eventual change in the law, the 
validity of standard composition-of-matter claims for isolated genes will 
not be addressed. The validity of short-sequence composition claims 
and some diagnostic methods claims, however, will be considered brief-
ly when relevant. 
Part I describes in some detail a generalized picture of gene patents 
and the types they typically contain. Part II analyzes the likelihood of 
WGS infringing the composition-of-matter claims in gene patents—that 
is, the claims for the genes themselves. Part III analyzes potential in-
fringement of the methods claims, which generally claim the process of 
determining gene mutations and using that information to diagnose a 
patient. Part IV concludes by briefly examining policy considerations 
and ways forward for personalized medicine based on whole-genome 
sequences. 
 
I.     WHAT DO GENE PATENTS LOOK LIKE? 
 
Much of the uncertainty surrounding gene patents comes from 
their variation. There is not a single set model for a gene patent, with 
standard language that can be parsed and analyzed to determine what 
any individual gene patent covers. Instead, each patent claims different 
variations on two types of inventions. First, gene patents typically claim 
isolated DNA molecules, including the entire sequence or a partial 
fragment of that sequence. Second, gene patents frequently claim a 
method of comparing the sequence of an individual with the known 
reference sequence (and possibly known mutations) and (sometimes) 
using that identification to draw medical conclusions. 
A bit of substantive background helps explain the two types of in-
vention claimed. Gene patents related to medicine fall into two main 
substantive classes.24 These classes can be roughly described as biotech-
nological and diagnostic, though the distinction is not always clear-cut 
 
 23 AMP II, 653 F.3d at 1329. The Federal Circuit had previously treated gene patents’ validi-
ty as a given. See, e.g., In re Deuel, 51 F.3d 1552, 1559 (Fed. Cir. 1995) (holding that the exist-
ence of a known method of isolating DNA molecules is “essentially irrelevant” to the question 
of the specific–claimed DNA’s obviousness without addressing section 101 patentability); In re 
Bell, 991 F.2d 781, 783 (Fed. Cir. 1993) (addressing obviousness of amino acid sequence, not 
section 101 patentability). 
 24 See, e.g., Christopher M. Holman, Trends in Human Gene Patent Litigation, 322 SCIENCE 
198 (2008) (classifying gene patents into four categories: therapeutic proteins, research tools, 
diagnostic testing, and forensic testing). Only therapeutic protein (such as erythropoietin or 
insulin) and diagnostic testing (such as BRCA1/2 for breast cancer predisposition or AspA for 
Canavan’s disease predisposition) are highly relevant to medicine. 
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at a practical level.25 The basic divide, however, describes both the 
commercial significance of gene patents and has some implication for 
which claims are likely to be included in the patent, argued over aca-
demically, and enforced through litigation.26 Biotechnological gene pa-
tents, whose value is in the protein they encode, are by far the most cur-
rently valuable gene patents. Amgen’s Patent No. 4,703,008 for 
erythropoietin provides one such example; the patent allows it to pre-
vent others from making recombinant erythropoietin, the basis of its 
Epogen anemia drug with over $2.5 billion in yearly sales.27 Diagnostic 
gene patents, on the other hand, cover genes whose commercial value is 
not primarily in producing large amounts of their protein product, but 
in evaluating how that product is already naturally produced in humans. 
As an example, Myriad Genetics’ Patent No. 5,747,282 (BRCA1 patent) 
covers the BRCA1 gene, which is related to a predisposition to breast 
cancer.28 Instead of producing the BRCA1 protein, as in a biotechnology 
gene patent, Myriad provides its own BRCAnalysis service, which in-
volves determining the sequence of the BRCA1 (and BRCA2) genes in a 
patient and then interpreting that information to find whether the pa-
tient has a predisposition to develop breast cancer.29 Myriad’s patents 
are used to prevent others from offering this service,30 which had sales 
of around $353 million in fiscal year 2011.31 
These two different functional classes of gene patents are not in 
themselves different for infringement analyses, but have to a certain 
extent resulted in different claim formats. The biotechnological gene 
patents’ most important claims are those for the full gene, whether de-
fined by gene or protein sequence, since the full gene is needed to pro-
duce the protein of interest. Diagnostic gene patents include those full-
gene central claims, but also require claims for shorter sequences, hy-
bridizing sequences, and methods of actually making diagnoses based 
on the information revealed by the gene sequence. These differences in 
patent construction will be discussed in more detail below as each type 
 
 25 For instance, a hypothetical gene patent covering insulin could have value both for the 
biotechnological production of therapeutic insulin and for a diagnostic test that could identify a 
predisposition towards developing diabetes. 
 26 Holman, supra note 24, at 198–99. 
 27 AMGEN, AMGEN 2010 ANNUAL REPORT AND FINANCIAL SUMMARY 171 (2011), available 
at http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-reportsannual (under the 
“Annual Reports” heading, click on “2010 Annual Report and 10-K” to download the report). 
 28 U.S. Patent No. 5,747,282 (filed June 7, 1995). 
 29 Ass’n for Molecular Pathology v. USPTO (AMP I), 702 F. Supp. 2d 181, 203 (S.D.N.Y. 
2010), aff’d in part, rev’d in part, 653 F.3d 1329 (Fed. Cir. 2011). 
 30 Id. at 204–06. 
 31 Turna Ray, Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing 
MDx Pipeline, GENOMEWEB PHARMACOGENOMICS REP. (Aug. 10, 2011), http://www.
genomeweb.com/dxpgx/posting-11-percent-revenue-growth-fy2011-myriad-focuses-growing-
mdx-pipeline. 
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of claim (composition-of-matter for the gene itself or method-of-
sequence-comparison) is addressed. 
 
A.     DNA Claims Cover Molecules Based on DNA or  
Encoded Protein Sequence 
 
Most gene patents rely on composition-of-matter claims to isolated 
nucleic acids. This type of claim also lies at the heart of many ethical and 
policy debates over gene patents: when people argue that gene patents 
cover genes within the human body, or that gene patents restrict the 
common heritage of humankind, these are the claims to which they 
refer.32 These claims come in several forms;33 however, one of the 
broadest types of claim, for short DNA sub-sequences, are very likely 
invalid in most cases.34 Common to these composition claims, based on 
USPTO guidelines,35 is language claiming an “isolated” nucleic acid, a 
term with important implications discussed below.36 
 
1.     Composition-of-Matter Claims Claim Sequences Specified as 
DNA, Protein-Encoding, or Short DNA Sub-Sequences 
 
Central to almost all gene patents are claims for isolated deoxyri-
bonucleic acids (DNA) with a specific sequence.37 To avoid falling out-
side the statutory subject matter of patents as defined in section 101 of 
the Patent Act, these claims claim isolated DNA, relying on the isolated 
products doctrine initially expounded in Parke-Davis & Co. v. H.K. 
Mulford Co.38 The USPTO relies on this doctrine; it does not define a 
 
 32 See, e.g., NUFFIELD COUNCIL ON BIOETHICS, THE ETHICS OF PATENTING DNA 21–23 
(2002). 
 33 See infra Part I.A.1. 
 34 See infra notes 49–58 and accompanying text. 
 35 Utility Examination Guidelines, supra note 22, at 1093. 
 36 See infra Part I.A.2. 
 37 Many patents claim nucleic acids in general, which includes ribonucleic acids (RNA). 
Since no genomic sequencing technology uses RNA (RNA is far more fragile than DNA, among 
other limitations), the distinction will be ignored here, and DNA will be assumed to be the 
relevant nucleic acid. 
 38 189 F. 95 (C.C.S.D.N.Y. 1911). The Federal Circuit recently held in AMP II that “an 
isolated DNA molecule is not a purified form of a natural material, but a distinct chemical 
entity.” AMP II, 653 F.3d 1329, 1352 (Fed. Cir. 2011). This implies that the initial rationale 
behind the “isolated” language may no longer apply; however, since the Federal Circuit held 
that the isolated DNA molecules in question were “markedly different—have a distinctive 
chemical identity and nature—from molecules that exist in nature,” based on the process of 
their isolation, id. at 1351, the practical impact of isolation making DNA patentable does not 
change. Furthermore, the court explicitly cited with approval the USPTO’s guidelines as 
longstanding practice with which Federal Circuit law should comport. Id. at 1354–55. 
PRICE.33-4 4/2/2012 3:56 PM 
1610 C ARD O Z O  L A W R E V IE W  [Vol. 33:4 
“gene patent” in its examination guidelines, but states that gene discov-
ery may form the basis for a patent if the gene is “isolated from its natu-
ral state and . . . separate[d] . . . from other molecules naturally associat-
ed with it.”39 These claims for isolated DNAs come in three primary 
forms: the entire gene defined by DNA sequence, the entire gene de-
fined by encoded amino acid sequence, and a fragment of the gene de-
fined by DNA sequence. These three forms of claims each have a specif-
ic function within the realm of gene patents. 
The most obvious claim in a gene patent is for an isolated DNA 
identified by its DNA sequence.40 This can be claimed as a 100% se-
quence match; claim 2 of the BRCA1 patent above claims “[t]he isolated 
DNA of claim 1, wherein said DNA has the nucleotide sequence set 
forth in SEQ ID NO:1.”41 Frequently, some flexibility in the match is 
provided; in the erythropoietin (EPO) patent, claim 1(b) claims a “puri-
fied and isolated DNA sequence encoding erythropoietin, said DNA 
sequence selected from the group consisting of [specified sequences 
and] DNA sequences which hybridize under stringent conditions to 
[those sequences].”42 Hybridization under stringent conditions is possi-
ble without 100% sequence identity (and must be, for that part of the 
claim to be independently valuable). 
The next type of claim in many gene patents is for an isolated DNA 
encoding a protein, with the DNA identified by the sequence of the en-
coded polypeptide. Myriad’s BRCA1 patent has as claim 1 “[a]n isolated 
DNA coding for a BRCA1 polypeptide, said polypeptide having the 
amino acid sequence set forth in SEQ ID NO:2.”43 Miami Children’s 
Hospital Research Institute’s Patent No. 5,679,635 for ASPA (ASPA 
patent), a gene related to Canavan’s disease, similarly claims as claim 1 
“[a]n isolated nucleic acid molecule comprising[] (a) a nucleic acid se-
quence encoding a human aspartoacylase polypeptide.”44 These claims 
could potentially be invalid inasmuch as they claim DNA molecules not 
disclosed pursuant to the Patent Act’s section 112 written disclosure 
 
 39 Utility Examination Guidelines, supra note 22, at 1093. 
 40 Note that patents typically claim both the DNA strand and its (typically non-coding) 
counterpart; that is, both sides of the double helix are claimed. In the ASPA patent, for in-
stance, Claim 1(b) claims “a nucleic acid sequence fully complementary to nucleic acid se-
quence (a).” U.S. Patent No. 5,679,635 (filed Sept. 9, 1994). This typically does not change the 
analyses described in this Article, except inasmuch as were complementary DNA sequences not 
claimed, such absences would raise the remote possibility of a technical workaround unless 
such a workaround was held to be infringing. In any case, the issue generally does not arise 
since complementary strands are usually included. 
 41 U.S. Patent No. 5,747,282 (filed June 7, 1995). 
 42 U.S. Patent No. 4,703,008 (filed Nov. 30, 1984). 
 43 U.S. Patent No. 5,747,282 (filed June 7, 1995). 
 44 U.S. Patent No. 5,679,635 (filed Sept. 9, 1994). 
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requirement, but the additional sequences they claim are not relevant to 
WGS.45 
The third and certainly broadest type of claim in gene patents 
claims smaller sequences that are fragments of the gene or its non-
coding counterpart. The BRCA1 patent’s claim 5 claims “[a]n isolated 
DNA having at least fifteen nucleotides of the DNA of claim 1 [claiming 
any nucleic acid encoding the specified polypeptide]”;46 similarly, the 
ASPA patent claims in claim 1(c) “a nucleic acid sequence at least six-
teen nucleotides in length capable of hybridizing specifically with one of 
said nucleic acid molecules (a) or (b).”47 In his dissent in AMP II, Judge 
Bryson described the BRCA1 claim 5 as “breathtakingly broad,” and 
argued that it should be held invalid under section 101.48 
Although a fact-agnostic legal analysis of short-sequence claims’ 
invalidity is hard to construct—indeed, thousands of such claims have 
been permitted by patent examiners—recent theoretical and empirical 
analyses suggest that all or nearly all such patents are invalid as antici-
pated under section 102 of the Patent Act.49 A recent analysis of the 
BRCA1 claim 5 addressed both the expected coverage of such claims 
and their actual extent.50 The authors calculated the expected number of 
the claimed 15-base sub-sequences of BRCA1 (BRCA1 15-mers) in the 
human genome, assuming a random genomic ordering of bases, and 
found that an average of one in 600 possible 15-mers would be claimed; 
therefore, an average-length 10,000 base human gene would be expected 
to contain about fifteen claimed 15-mers.51 In an actual search for 
claimed sequences, they found over 340,000 claimed 15-nucleotide se-
 
 45 This type of claim relies on the redundancy of the genetic code (since there are sixty-four 
three-base codons and only twenty amino acids, most amino acids are encoded by multiple 
codons) to claim all sequences which could encode a particular protein. The number of se-
quences claimed is extremely large, given that the “usage-weighted geometric mean codon 
degeneracy per amino acid is 3.107.” Thomas B. Kepler et al., Metastasizing Patent Claims on 
BRCA1, 95 GENOMICS 312, 312 (2010). For instance, a twenty–amino acid protein (far shorter 
than any human gene) could potentially be encoded by 3.10720 DNA sequences—more than 
seven billion. 
 46 U.S. Patent No. 5,747,282 (filed June 7, 1995). 
 47 U.S. Patent No. 5,679,635 (filed Sept. 9, 1994). Presumably, a fifteen-nucleotide threshold 
was picked as a threshold of something approaching uniqueness in at least the human genome, 
since the odds of choosing any given fifteen-nucleotide sequence at random are (¼)15, or a little 
less than one in a billion. However, the human genome is not randomly arranged, and in fact 
such sequence matches occur far more frequently. Kepler, supra note 45, at 312–13. 
 48 AMP II, 655 F.3d 1329, 1379 (Fed. Cir. 2011) (Bryson, J., concurring in part and dissent-
ing in part). 
 49 Kepler et al., supra note 45, at 313. 
 50 Id. at 312–14. 
 51 Id. at 312–13. Judge Bryson cited a similar analysis in his AMP II dissent, stating that the 
BRCA1 ’282 patent’s Claim 6, covering fifteen-mers from the cDNA sequence (just the coding 
sequence, not the full-length gene), “covers portions of the cDNA of more than 4% of human 
genes. It also covers portions of the DNA of nearly all human genes.” AMP II, 653 F.3d at 1379 
(Bryson, J., concurring in part and dissenting in part). 
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quences in human chromosome 1 alone.52 Breadth alone is not a reason 
for invalidity.53 However, this extraordinary breadth makes anticipation 
under section 102’s novelty requirement very likely for most, if not all of 
these claims. Before gene patenting became widespread (and therefore 
before the vast majority of gene patents were filed),54 many thousands of 
sequences were deposited in publicly available databases, such as 
Genbank,55 which is likely considered a “printed publication” for sec-
tion 102 novelty purposes under courts’ liberal readings of that provi-
sion.56 Since one in any 600 random 15-mers, on average, is claimed as a 
BRCA1 15-mer,57 it is very likely that the claim is anticipated by previ-
ously disclosed and publically available sequences. Indeed, fifteen bases 
of the natural BRCA1 DNA sequence (ignoring the degeneracy of the 
genetic code) appeared in a GenBank submission more than a year be-
fore the BRCA1 patent was filed, thus anticipating claim 5 under sec-
tion 102(b).58 A comprehensive similar analysis for all gene patents is far 
beyond the scope of this paper, but would likely reveal anticipating se-
quences for most, if not all, short-sequence claims in gene patents. 
Overall sub-sequence claims are almost certainly anticipated by se-
quences publicly deposited before patent filing or invention. 
 
 52 Kepler et al., supra note 45, at 313. 
 53 Potentially, such extraordinary and logically unbounded breadth might render a claim 
vulnerable to challenge under the section 112 written-description requirement. See, e.g., AMP 
II, 653 F.3d at 1379 (Bryson, J., concurring in part and dissenting in part) (“Of course, in light 
of its breadth, claim 5 of the ’282 patent is likely to be invalid on other grounds, and thus a 
ruling as to patent-eligibility with respect to that claim may be superfluous.”). This possibility 
will not be explored in depth in this Article since section 102 anticipation arguments, infra, 
make invalidity almost certain in any case. 
 54 See, e.g., DPD: About the DNA Patent Database, DNA PATENT DATABASE, 
http://dnapatents.georgetown.edu/aboutdpd.htm (last updated Feb. 1, 2012). 
 55 GenBank Overview, NAT’L CTR. FOR BIOTECHNOLOGY INFO., http://www.ncbi.nlm.nih.
gov/genbank (last updated May 3, 2011). 
 56 For prior art to be a printed publication, it “must have been sufficiently accessible to the 
public interested in the art; dissemination and public accessibility are the keys to the legal 
determination whether a prior art reference was ‘published.’” Constant v. Advanced Micro-
Devices, Inc., 848 F.2d 1560, 1568 (Fed. Cir. 1988). Genbank and other online databases are the 
dominant, and frequently required, means of making sequence information available to the 
scientific community. GenBank Overview, supra note 55. The Federal Circuit has previously 
held that inclusion in a publicly accessible database (in the particular case, Westlaw) was suffi-
cient to constitute a printed publication. In re Lister, 583 F.3d 1307, 1316 (Fed. Cir. 2009). 
 57 Kepler et al., supra note 45, at 312. 
 58 The fifteen-base sequence AAGGCAAAAACAGAA is found at nucleotide 2942 of the 
sequence for the human T-cell receptor beta variable region, deposited November 4, 1993, well 
over a year before the BRCA1 patent was filed on June 6, 1995. Homo Sapiens T-cell Receptor 
Beta Variable Region (TCRBV) Gene Locus, Genomic Sequence, NAT’L CTR. FOR BIOTECHNOLO-
GY INFO., http://www.ncbi.nlm.nih.gov/nuccore/467918 (last visited Feb. 15, 2012). 
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2.     In General, Composition-of-Matter DNA Claims Are for 
“Isolated” Nucleic Acids 
 
A crucial aspect of all three forms of composition-of-matter claims 
is that they almost always claim an “isolated” nucleic acid.59 There is no 
standard definition of “isolated” used in all patents, nor would such a 
definition be determinative, since each patentee may be his own lexicog-
rapher.60 Unfortunately, the meaning of “isolated” could end up being 
dispositive in a significant number of cases, since it critically qualifies 
what is claimed. It is impossible to completely address the meaning of 
“isolated,” since meanings differ and would only be fully construed at 
the Markman phase61 of a gene patent trial—and those trials have been 
quite rare, particularly with respect to diagnostic testing.62 However, a 
reliable working sense of what “isolated” could plausibly mean can be 
derived from an examination of representative patents and relevant 
precedent, most importantly the Federal Circuit’s decision in AMP II. 
Examples from sample DNA patents show some measure of varia-
tion with respect to the meaning of the term “isolated,” but cover essen-
tially the same features. The BRCA1 patent includes the following in its 
definition section: 
An “isolated” or “substantially pure” nucleic acid (e.g., an RNA, 
DNA or a mixed polymer) is one which is substantially separated 
from other cellular components which naturally accompany a native 
human sequence or protein, e.g., ribosomes, polymerases, many other 
human genome sequences and proteins. The term embraces a nucleic 
acid sequence or protein which has been removed from its naturally 
occurring environment, and includes recombinant or cloned DNA 
isolates and chemically synthesized analogs or analogs biologically 
synthesized by heterologous systems.63 
The district court in AMP I accepted the plain meaning of this def-
inition, construing the term “isolated DNA” to mean “a segment of 
DNA nucleotides existing separate from other cellular components 
normally associated with native DNA, including proteins and other 
DNA sequences comprising the remainder of the genome, and includes 
both DNA originating from a cell as well as DNA synthesized through 
chemical or heterologous biological means.”64 
 
 59 Alex Osterlind, Staking a Claim on the Building Blocks of Life: Human Genetic Material 
Within the United States Patent System, 75 MO. L. REV. 617, 624–25 (2010). 
 60 Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996). 
 61 Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). 
 62 Holman, supra note 24, at 198–99. 
 63 U.S. Patent No. 5,747,282 (filed June 7, 1995) (emphasis added). 
 64 AMP I, 702 F. Supp. 2d 181, 217 (S.D.N.Y. 2010). 
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No definition of “isolated” is provided in the ASPA patent, but ref-
erence is made to Patent No. 5,227,292 for common definitions of terms 
of art, including “isolated.” That patent states that “isolated nucleic ac-
id . . . is defined as nucleic acid isolated from its natural environment 
(e.g. cDNA or a fragment of genomic DNA) . . . .”65 
The Federal Circuit provided only a partial description of “isola-
tion” in AMP II.66 More broadly, the court could not define “isolated 
DNA” once and for all, since each patent may define the term in its own 
terms. The court did describe isolated DNA in terms supporting the 
conception of isolation as generally a physical and chemical process 
rather than, for instance, an informational one.67 After describing native 
DNA, which “exists in the body as one of forty-six large, contiguous 
DNA molecules[, each] an integral part of a larger structural complex, a 
chromosome,”68 the court characterized isolated DNA as “a free-
standing portion of a native DNA molecule, frequently a single gene[, 
that] has been cleaved (i.e., had covalent bonds in its backbone chemi-
cally severed) or synthesized to consist of just a fraction of a naturally 
occurring DNA molecule.”69 This language confirms that “isolated 
DNA” is chemically isolated from its genetic neighbors; it also “must be 
removed from its native cellular and chromosomal environment.”70 This 
 
 65 U.S. Patent No. 5,227,292 (filed July 12, 1990). 
 66 AMP II, 653 F.3d 1329, 1351–53 (Fed. Cir. 2011). 
 67 An argument could be made that “isolation” should refer to informational isolation 
rather than physical separation. E-mail from Robert Cook-Deegan, Dir., Duke Inst. for Genome 
Scis. & Pol’y Ctr. for Genome Ethics, Law & Pol’y, to author (July 17, 2011) (on file with au-
thor). Under this conception, isolation is not an actual physical separation from other cellular 
components by purification and from other DNA sequences by breaking covalent bonds. Id. 
Instead, a DNA sequence is “isolated” by the very process of detecting, sequencing, or selective-
ly hybridizing with a probe. Id. If we imagine the soup of DNA molecules in a biochemical 
preparation as a crowd of individuals, physical isolation would be pulling a person out of the 
crowd and having that person stand off to the side; this informational concept of isolation 
would instead be carried out by pointing out an individual (detection), getting her name and 
description (sequencing), or having her friend meet up with her while wearing bright clothing 
that could be identified from a distance (hybridization). The word “isolated” is certainly used in 
a non-physical, informational sense, such as “to isolate a problem”; in the context of composi-
tion-of-matter claims claiming a physical DNA molecule, however, it seems less plausible that 
“isolation” would refer to a non-physical identification or tagging process without actual physi-
cal separation. This is borne out by the language of the sample claims above; the BRCA patent 
defines “isolated” DNA as “removed from its naturally occurring environment,” U.S. Patent No. 
5,747,282 (filed June 7, 1995) (emphasis added), not merely detected, sequenced, or hybridized. 
  Judge Bryson, in his dissent in AMP II, made a parallel argument that “[I]f we are to 
apply the conventional nomenclature of any field to determine whether Myriad’s isolated DNA 
claims are ‘new,’ it would seem to make more sense to look to genetics, which provides the 
language of the claims, than to chemistry.” AMP II, 653 F.3d at 1376 (Bryson, J., concurring in 
part and dissenting in part). The genetics nomenclature is an informational one: “From a ge-
netic perspective, that [composition] claim covers one ‘composition of matter’—the BRCA1 
gene.” Id. However, as described in detail infra, this reasoning was not adopted by the majority. 
 68 AMP II, 653 F.3d at 1352. 
 69 Id. at 1351. 
 70 Id. at 1352. 
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description, however, does not explicitly set the boundaries of “isola-
tion”—that is, how isolated does a DNA molecule have to be to be “iso-
lated DNA?” 
Neither the patent-based definitions nor AMP II’s description 
specifies the necessary degree of isolation, or the boundaries of that def-
inition. This is not wholly surprising; in an individual diagnostic testing 
case, the targeted sequence usually is precisely what is covered by the 
patent claim. If a researcher amplifies a patient’s BRCA2 gene to look 
for mutations, that amplified DNA sequence is precisely what is de-
scribed in the claims of Myriad’s BRCA2 patents. In the case of WGS, to 
the contrary, sequencing is not targeted, so the boundary of what counts 
as “isolated” becomes significantly more important, as will be described 
below.71 
While the definitions available do not specify boundaries, they do 
suggest a set of potential breadth-based definitions for isolation, which 
are summarized in Table 1. The narrowest definition conceivable would 
seem to be perfect and complete isolation: only the sequence described, 
with no flanking sequences (i.e., nucleotides attached to either end), no 
bound proteins or other nucleic acids (e.g., ribosomes, polymerases, or 
histones), and no other cellular components or structures (e.g., lipid 
membranes). This seems to be the definition hinted at, though not stat-
ed, by the Federal Circuit.72 A slight broadening would include only 
substantial separation from those other elements, rather than total sepa-
ration. Finally, a still broader definition would include substantial sepa-
ration from other cellular elements, but would allow longer flanking 
DNA sequences.73 How long can flanking sequences be while retaining 
“isolation”? In an intuitive, plain-meaning sense, “isolated” most likely 
captures isolation from adjacent genes, but could potentially include 
 
 71 See infra Part II. 
 72 Judge Moore stated that, “Instead of being connected to many thousands of additional 
nucleotides at the 3’ and 5’ ends of the sequence in question, as is the case in the chromosome, 
the isolated DNA molecules terminate in, for example, a hydroxyl and a phosphate group, 
respectively.” AMP II, 653 F.3d at 1363 (Moore, J., concurring in part). This language implies a 
very stringent definition of “isolated DNA” as a chemically defined single molecule, with pre-
cisely delineated ends—that is, not as a mixture of a population of very similar DNA fragments 
with some impurities coming from other cellular components. The majority opinion echoes 
this conception, less obviously, in its repeated description of isolated DNAs as “distinctive 
chemical molecules,” id. at 1351 (majority opinion), or having a “distinctive chemical identity,” 
id. at 1351–52, 1354. 
 73 This would involve some linguistic twisting for the nucleic-acid-specified claims, since it 
would construe “isolated” to refer to the nucleic acid as opposed to non-nucleic-acid cellular 
components (i.e., including nontrivial flanking sequences), but would then presumably refer 
only to the coding region of that nucleic acid for purposes of specifying the sequence. This 
dichotomy does not occur in the composition claims based on the encoded protein or on the 
acid containing the short sequence overlaps, since in each of these types of claim it is clear that 
the nucleic acid merely contains the identifying sequence, and does not consist entirely of that 
sequence. 
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them under a very broad reading of the claims. “Isolated,” however, 
certainly includes separation from the chromosome taken as a whole, as 
the court laid out in AMP II.74 Therefore, for the remainder of this anal-
ysis, the broadest feasible construction of “isolated nucleic acid” will be 
used: a nucleic acid sequence which is substantially isolated from other 
cellular components but which may contain non-trivial flanking se-
quences, including other genes but not a large fraction of the chromo-
some. 
 
Table 1.     Potential Definitions of “Isolated Nucleic Acid” 
 








Substantially none Minimal sequences 
Broad Non-trivial Flanks Substantially none 
Non-trivial sequences, but 









B.     Method Claims Usually Cover the Comparison of  
Sequence to References 
 
The second important class of claims frequently found in gene pa-
tents contains method claims relating to using the genetic information 
for diagnostic purposes. Obviously, this type of claim typically only ap-
pears (or at least is only of commercial importance) in diagnostic gene 
patents. These method claims generally comprise two main steps, which 
are sometimes conflated. The first step (when included) involves deter-
mining (or observing or detecting) the sequence of the gene as possessed 
by the patient, and the second step involves comparing that sequence to 
 
 74 AMP II, 653 F.3d at 1351–53 (contrasting isolated DNA with native DNA as found in a 
large DNA molecule as part of a chromosome). Aside from the extraordinary lexical broadness 
that would be required to construe an isolated DNA as including an entire chromosome, that 
broad a definition would be practically useless. If the meaning of an “isolated DNA” including a 
specified sequence could encompass the entire chromosome containing that sequence, if sepa-
rated from other cellular components, the vast majority of DNA patents drafted in this form 
would be invalid, since they would be anticipated by the first patent claim for any sequence 
within that chromosome. 
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the sequences identified in the gene patent. A third step may sometimes 
be specified, sometimes only as a “wherein” clause, involving using the 
differences between the sequences to diagnose, for example, a predispo-
sition to the disease connected to the gene. These method claims are less 
uniformly written, but a few examples demonstrate their general formu-
lation. Duke’s Patent No. 5,508,167 (covering ApoE, a gene associated 
with Alzheimer’s disease) has as claim 1: 
A method of detecting if a subject is at increased risk of developing 
late onset Alzheimer’s disease (AD) comprising directly or indirectly: 
detecting [step 1] the presence or absence of an apolipoprotein E type 
4 isoform (ApoE4) in the subject; and observing whether or not the 
subject is at increased risk [step 3] of developing late onset AD by ob-
serving if the presence of ApoE4 is or is not detected [step 2], wherein 
the presence of ApoE4 indicates said subject is at increased risk of 
developing late onset AD [step 3].75 
Myriad’s Patent No. 5,753,441 (again, covering BRCA1) includes 
steps 2 and 3 in its claim 1: 
A method for screening germline of a human subject for an altera-
tion of a BRCA1 gene which comprises comparing [step 2] sequence 
of a BRCA1 gene or BRCA1 RNA from a tissue sample from said 
subject or a sequence of BRCA1 cDNA made from mRNA from said 
sample with germline sequences of wild-type BRCA1 gene, wild-type 
BRCA1 RNA or wild-type BRCA1 cDNA, wherein a difference in the 
sequence of the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA of the 
subject from wild-type indicates an alteration in the BRCA1 gene in 
said subject [step 3].76 
While method claims are less uniformly written than the composi-
tion-of-matter claims described above, they tend to claim some varia-
tion of the three steps above; they can be broadly classed based on 
whether they explicitly include a sequencing step, which the Federal 
Circuit has indicated may be crucial for their validity.77 The three-step 
process is certainly a prototypical method of diagnosing a disease based 
on gene sequence, and will be used in the analysis of WGS’s potential 
infringement of individual gene patents. 
Overall, though both method claims and composition-of-matter 
claims have some variability in their individual drafting, they are con-
strained by both practice (e.g., the relatively consistent types of uses for 
biotechnological and diagnostic patents78) and rule (e.g., the USPTO’s 
Utility Examination Guidelines which pre-approve “isolated” nucleic 
 
 75 U.S. Patent No. 5,508,167 (filed Apr. 13, 1994) (emphasis and step notation added). 
 76 U.S. Patent No. 5,753,441 (filed Jan. 5, 1996) (emphasis and step notation added). 
 77 AMP II, 653 F.3d at 1355–57. 
 78 See supra notes 24–31 and accompanying text. 
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acid claims79) to a certain domain of potential claim scope. Although a 
comprehensive analysis of all gene patents is far beyond the scope of this 
work, the claim structures described above are enough to analyze WGS 
infringement at a broad level. The following text lays out that analysis 
for composition claims (Part II) and method claims (Part III). 
 
II.     DOES WHOLE-GENOME SEQUENCING INFRINGE COMPOSITION-OF-
MATTER CLAIMS TO ISOLATED GENES? 
 
Gene patents are not aimed at including general sequencing meth-
ods, so their claims lack the broad scope which would easily span multi-
ple methodological variations. Instead, as described above,80 gene patent 
claims focus specifically on two types of inventions: composition claims 
on DNA molecules including the entire or partial sequence, and method 
claims based on sequence comparison. Whether WGS infringes the first 
type of claim—that is, the claims for DNA molecules—depends on the 
specific sequencing technology used. Whether WGS infringes the se-
cond type of claim, for drawing medical correlations, depends less on 
the technology itself and more on the commercial structure surrounding 
the sequencing. However, this general class of correlation claim is inva-
lid under AMP II81 based on the reasoning of Bilski v. Kappos82 and 
Prometheus Laboratories v. Mayo Collaborative Services,83 unless se-
quence-determining steps are explicitly included in the method. 
The determination of whether WGS infringes a typical extant 
composition-of-matter gene patent claim depends on the precise con-
tours of the sequencing technology employed—namely, whether the 
technology ever actually creates or uses the specific “isolated” nucleic 
acids claimed in the patent. If those specific claimed nucleic acids are 
never created or used in the sequencing process, there is no infringe-
ment. For these claims, technology determines infringement. Several 
different versions of sequencing technology have been developed to read 
entire genomes. This Article focuses first on the two sequencing tech-
niques which have been well-developed and validated, and which are in 
common use today: hierarchical sequencing and shotgun sequencing. It 
also describes and analyzes a novel and still developing technique: 
nanopore sequencing. The contours of possible infringement are sub-
stantially different for the different sequencing techniques. 
 
 79 Utility Examination Guidelines, supra note 22, at 1093. 
 80 See supra Part I. 
 81 AMP II, 653 F.3d at 1355–58. 
 82 130 S. Ct. 3218 (2010). 
 83 628 F.3d 1347 (Fed. Cir. 2010), cert. granted, 131 S. Ct. 3027 (2011). 
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An initial technical point must be made about DNA sequencing as 
it is generally described. The term “sequencing” is unfortunately used 
for two distinct processes, though both do, in fact, determine sequences 
of bases in a nucleic acid. On a smaller scale, sequencing generally refers 
to a specific experiment whereby the nucleotide order of a nucleic acid is 
determined.84 This is the type of sequencing meant in the phrase “se-
quence a gene.” This type of sequencing, however, faces a technical limi-
tation: it can only determine the sequence of a relatively small stretch of 
DNA—generally, only several hundred bases. This is the central chal-
lenge of sequencing—at most 1000 bases can be determined in a single 
reaction,85 but the smallest human chromosome is made up of approxi-
mately forty-seven million base-pairs and contains hundreds of genes.86 
Enter large-scale sequencing. Used in this sense, “sequencing” refers not 
to the small-scale sequencing experiments which actually “read” bases 
(e.g., ACCTGTAACG . . .), but to the assembling of many such shorter 
sequences (determined from the smaller-scale sequencing reactions) to 
create accurate sequences for larger stretches of DNA. A useful (if non-
linear) analogy might be a microfiche reader with poorly functioning 
movement controllers—on a small scale, one “reads” the microfiche 
based on whatever fragment is viewable at any given time, and in a large 
scale, one could “read” the document by recording each of those frag-
mentary views and then fitting them together into one coherent whole. 
For DNA sequencing, the traditional mode of small-scale reading is the 
well-established Sanger sequencing reaction; the principal differences in 
large-scale reading form the distinction between the main techniques of 
sequencing used today. 
 
A.     “Traditional” Whole-Genome Sequencing Techniques: De Novo and 
Reference Sequence Assembly of Shotgun Sequences 
 
The two main well-established techniques for WGS both rely on 
the traditional paradigm of two-step sequencing described above: that 
is, essentially random and duplicative shotgun small-scale sequencing 
 
 84 In particular, sequencing today is overwhelmingly performed by the Sanger method, first 
described in 1977. F. Sanger et al., DNA Sequencing with Chain-Terminating Inhibitors, 74 
PROC. NAT’L ACAD. SCI. 5463 (1977). 
 85 Erik Pettersson et al., Generations of Sequencing Technologies, 93 GENOMICS 105, 106 
(2009). Note that experimental apparatuses exist to perform many such sequencing reactions in 
parallel—up to 384 at once, in fact—but this still generates separate sequences that then need to 
be non-trivially joined together. Id. 
 86 See generally M. Hattori et al., The DNA Sequence of Human Chromosome 21, 405 NA-
TURE 311 (2000). 
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followed by assembly into a larger whole.87 In each technique, the small-
scale sequencing follows the same procedure. First, genomic DNA is 
isolated from other cellular components, including not only lipid mem-
branes and general cellular proteins, but also components more closely 
associated with DNA, such as histones and polymerases. In an ordinary 
sequencing experiment, many copies of the genomic DNA are isolated 
in this step.88 Second, the genomic DNA is broken down into small 
fragments, generally ranging from twenty-five to 1000 bases in length.89 
Third and finally (in the small-scale sequencing stage), those fragments 
are sequenced base-by-base, frequently using the Sanger method, but 
potentially using other techniques.90 At this stage, the two techniques 
diverge, although not in a way that is relevant for infringement analysis. 
In de novo assembly, the pieces are computationally assembled accord-
ing to overlap without any external reference,91 whereas in reference-
sequence assembly, pieces are overlaid on a reference sequence (most 
typically, the first reference human genome sequence) to place them in 
order.92 As a rough analogy, de novo assembly is like putting together a 
jigsaw puzzle just based on matching edges, whereas reference sequence 
assembly uses a picture that is similar, but not identical, to the puzzle as 
a guide for putting the pieces in place.93 
 
 87 A historically informed reader might wonder about a different set of two WGS tech-
niques, which were the competing two techniques in the race to sequence the human genome 
for the first time. In brief, one technique (used by Celera Genomics) was de novo assembly of 
shotgun sequences, which will be described infra. See generally J. Craig Venter et al., The Se-
quence of the Human Genome, 291 SCIENCE 1304 (2001). The other technique (used by the 
collaborative public effort), known as BAC-to-BAC, focused on generating a large-scale crude 
physical map of the genome using restriction site analysis of Bacterial Artificial Chromosomes 
containing large (approximately 150,000 bases) segments of DNA, and then mapping smaller 
sequences onto that large-scale physical map. See generally Int’l Human Genome Sequencing 
Consortium, Initial Sequencing and Analysis of the Human Genome, 409 NATURE 860 (2001). 
BAC-to-BAC sequencing, however, only needs to be done once for any given genome—once a 
single genomic sequence of relatively high quality has been completed, that sequence can serve 
as a rather less crude physical map for assembling small-scale sequences when sequencing 
additional individuals’ genomes of the same species. Id. The analog of BAC-to-BAC sequencing 
in current efforts to sequence individual human genomes is reference sequence assembly of 
shotgun sequences—but the experimentally cumbersome process of creating the initial physical 
map using BAC-to-BAC is no longer necessary for human sequencing. 
 88 Ng & Kirkness, supra note 10, at 216. 
 89 Id. 
 90 Id. at 216–17. 
 91 Id. at 216. 
 92 Id.; David A. Wheeler et al., The Complete Genome of an Individual by Massively Parallel 
DNA Sequencing, 452 NATURE 872, 876 (2008). 
 93 The question might arise as to why anyone would use a de novo approach, which is much 
more computationally intensive. The answer is that de novo assembly is much better at dealing 
with novel regions that are not present in the reference sequence. Ng & Kirkness, supra note 10, 
at 216. On the other hand, de novo assembly can fail to properly take account of repeating 
segments, which are frequent in the human genome. Id. 
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The question of infringement for these two established sequencing 
techniques is: Do these techniques make or use an “isolated” nucleic 
acid as specified by one of the typical sequence specifications in gene 
patent composition-of-matter claims? These two parts will be analyzed 
separately: isolation will be analyzed first, followed by the different types 
of sequence specification described above. 
“Isolated,” as discussed previously, can take a range of different 
plausible meanings. All of the plausible meanings of an “isolated nucleic 
acid” include isolation from proteins and other cellular materials, and, 
on this count, both of the traditional DNA sequencing techniques likely 
are covered.94 The question of whether DNA in genetic sequencing is 
“isolated” from other genetic material—that is, from flanking sequenc-
es—is only slightly more complicated. Both de novo assembly and refer-
ence sequence assembly involve the creation and use of fragmented 
DNA sequences.95 In current sequencing practice, these fragments are 
usually between 25 and 1,000 bases in length.96 Under the Narrowest or 
Narrow definition, these fragments could potentially include minor 
flanking sequences sufficient to defeat isolation. However, under the far 
more likely Broad definition, as was adopted in the district court’s con-
struction in AMP I,97 (or, a fortiori, under the Broadest definition) as 
long as these flanking sequences did not include other genes, the frag-
ment would be considered “isolated DNA.” 
Since either of the main techniques likely creates and uses “isolat-
ed” DNA as claimed in composition claims, the remaining question is 
whether the fragments are those specified in the gene patent claims by 
one of the three general specification methods. This analysis first re-
quires a close look at the size of the fragments and of human genes as 
differently specified. 
The first two main types of sequence specification are functionally 
equivalent here (assuming both types are valid).98 In each, infringement 
requires an isolated nucleic acid that is essentially the complete se-
quence, in some cases with some flexibility as to whether the match 
needs to be perfect.99 Therefore, for these claims to be infringed, the 
 
 94 It is true that if “isolated” is construed to mean completely separated from other cellular 
components, then DNA sequencing may fail to infringe if the particular experimental protocol 
fails to perfectly purify the DNA. This construction is unlikely, however—relatively little in the 
biological world is ever 100% pure, nor does it usually need to be. If, as seems much more 
likely, “isolated” means substantially or operationally isolated from other cellular compo-
nents—that is, the sense of “isolated” that practically is necessary for use of DNA as DNA—
then sequencing almost certainly involves DNA that is “isolated” from other cellular compo-
nents. 
 95 Ng & Kirkness, supra note 10, at 216. 
 96 Id. 
 97 AMP I, 702 F. Supp. 2d 181, 216–17 (S.D.N.Y. 2010). 
 98 See supra notes 37–45 and accompanying text. 
 99 See supra notes 40–42 and accompanying text. 
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fragment generated and used in the WGS process—that is, the frag-
ments between twenty-five and 1000 bases used in the small-scale se-
quencing—must contain the entire gene sequence. The identity analysis 
above shows that every potential sequence is expected to occur multiple 
times in the process, so the remaining constraint is size. For instance, if 
a gene is 1200 bases long, then even a perfectly aligned 1000 base frag-
ment will not contain the entire sequence. Therefore, whether a WGS 
technique infringes the whole-gene-sequence–defined composition 
claims of a gene patent depends on the specific size of the fragments 
generated, and whether the gene claimed is smaller than that size. Con-
sidering actual size distributions, a very small (but not zero) number of 
genes could be the subject of whole isolated gene claims which would be 
infringed by current sequencing methods. Human genes vary tremen-
dously in size, from hundreds to millions of bases.100 There are certainly 
human genes which can be found in their entirety on 1000 base frag-
ments created as part of WGS. There are not, however, very many.101 
BRCA1, for instance, spreads over more than 81,000 bases of genomic 
DNA. Overall, it seems that few composition claims for whole isolated 
genes would be infringed by traditional WGS sequencing. 
The third type of sequence claim is much more widely applicable, 
but is also significantly less likely to be valid. This type of claim claims 
isolated nucleic acids with a matching stretch that consists of a much 
smaller portion of the claimed gene—often fifteen or sixteen bases long. 
Effectively any fragments used in WGS that actually contain a portion of 
the claimed gene would meet this definition.102 Since these fragments 
 
 100 TOM STRACHAN & ANDREW P. READ, HUMAN MOLECULAR GENETICS 253–54 (3d ed. 
2004). Note that most human genes contain non-coding stretches, so that the actual coding 
portion of the gene is much smaller than its genomic extent. Id. at 254. Since WGS involves 
sequencing genomic DNA, however, and not only the coding sequences of the genome, the 
genomic extent of genes (e.g., introns and exons) is the relevant quantity. 
 101 This Article focuses on protein-encoding genes—that is, genes which code for a protein 
that will be produced by cells. The analysis of gene coverage is easily extendable to ribosomal 
RNA or transfer RNA genes—that is, genes which code for RNA that performs functions in the 
cell itself, rather than being encoded into a protein (in the common nucleic-acid-as-blueprint 
analogy, this would be the use of blueprints as flyswatter, window-covering, or wall art rather 
than as a plan to build something). What is not so easy to consider, however, is small interfer-
ing RNA genes (siRNA), which are only a few dozen bases in length. siRNA genes inhibit the 
expression of other genes, and have a wide range of potential uses. See generally Stefan Maas, 
Gene Regulation Through RNA Editing, 10 DISCOVERY MEDICINE 379 (2010); Mouldy Sioud, 
Promises and Challenges in Developing RNAi as a Research Tool and Therapy, 703 METHODS 
MOLECULAR BIOLOGY 173 (2011); S. Patrick Walton et al., Designing Highly Active siRNAs for 
Therapeutic Applications, 277 FEBS J. 4806 (2010). However, since siRNA patents are only just 
beginning to emerge, Charlie Schmidt, Negotiating the RNAi Patent Thicket, 25 NATURE BIO-
TECHNOLOGY 273 (2007), they are not considered in depth here. Should they become a signifi-
cant patent presence, the two traditional WGS techniques would almost certainly infringe, since 
they would function essentially as valid short-sequence gene claims; however, nanopore se-
quencing and other single-molecule methods would remain non-infringing. 
 102 The trivial exception consists of those cases where a fragment included less than fifteen 
(or so) bases of the gene at one end—for instance, a fragment which had as its last twelve bases 
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are almost certainly “isolated,” these claims would very likely be literally 
infringed by either traditional technique of WGS. However, as described 
above, this form of claim is very likely invalid in all or nearly all gene 
patents,103 so this form of infringement should present little in the way 
of a practical problem. There are exceptions: less-sophisticated or less-
funded actors who may be deterred by the mere threat of literal in-
fringement without consideration of its vulnerability to legal challenge, 
and those who may believe, as described above, that “isolated” has a 
fundamentally different meaning in diagnostic cases.104 
Overall, it appears that the two traditional WGS techniques are 
likely to infringe a small number of whole-gene claims and a much larg-
er number of potentially invalid short-sequence claims. Notably, either 
of these processes could be modified to work around all, or almost all of 
the whole-gene patent claims by changing the size of the fragments gen-
erated; with fragment sizes below a few hundred bases, no whole-gene 
claims would be infringed. This process would not be costless—the 
fragment sizes used were picked for computational and experimental 
reasons, and changing them would require altering protocols and poten-
tially adding additional redundancy-checking to avoid introducing se-
quencing errors—but is certainly possible. 
One potential counterargument that could be made for infringe-
ment which obviates the size workaround is that the fragments are reas-
sembled in the process of whole sequence generation. This argument, 
however, ignores the information/chemical distinction. DNA is a chem-
ical compound, and it is as such that gene patents covering it are grant-
ed. It is also conceived as a set of information; however, this is not the 
subject of composition-of-matter gene patents.105 The chemical frag-
ments are never reassembled into larger pieces in the process of se-
quence generation; only the information fragments are rejoined. There-
fore, the process of assembling the information cannot itself constitute a 
source of patent infringement. 
 
the first twelve bases of the claimed gene. Since all possible fragments of the specified size are 
stochastically expected, this exception has no practical effect. 
 103 See supra notes 49–58 and accompanying text. 
 104 See supra note 67. 
 105 The Federal Circuit’s description of the isolated DNA covered by the composition-of-
matter claims describes them exclusively as chemicals. AMP II, 653 F.3d 1329, 1349–55 (Fed. 
Cir. 2011). DNA sequences are described as informational constructs in the patent and the 
opinion; however, those sequences are not compositions of matter, but the subjects of method 
claims covering comparison of different sequences. Id. at 1355–57. DNA sequences (not mole-
cules) as covered by the method claims are analyzed infra Part III. 
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B.     A Novel Sequencing Technique: Nanopore Sequencing 
 
In stark contrast to the relatively familiar procedures of two-scale 
sequencing, the new and still developing technology of nanopore se-
quencing relies on completely different processes and, consequently, 
requires an alternate infringement analysis. It is worth noting at the 
outset that nanopore sequencing is perhaps years away from commer-
cial use. However, because of the radically different technology in-
volved, it appears to be one of the most promising options for the actual 
widespread advent of WGS—that is, for the popular conception of a 
machine which can read a person’s genome, as opposed to a relatively 
time-consuming and laborious process that needs to be performed 
offsite. Finally, nanopore sequencing, though only one of a set of new 
and developing third-generation sequencing technologies, exemplifies 
many of the common features of these new technologies, such as very 
long read lengths and single-molecule–based sequencing.106 As such, it 
merits careful consideration in the WGS arena. 
Nanopore sequencing aligns much more closely with lay views 
(and legal analogies) of DNA sequencing. In particular, it actually in-
volves sequentially reading a long stretch of DNA, one base at a time.107 
The concept is simple. In essence, nanopore sequencing involves feeding 
a long strand of DNA through a very small hole (so that only one base at 
a time fits in the hole) and determining the shape of each base as it pass-
es through the hole by measuring how it blocks the hole.108 
Although conceptually simple, nanopore sequencing is technically 
challenging.109 The experimental apparatus is key. A nanopore is created 
in some barrier; a nanopore is simply a hole of around one nanometer 
in diameter, and can be protein embedded in a membrane,110 an etched 
 
 106 Eric E. Schadt et al., A Window into Third-Generation Sequencing, 19 HUM. MOLECULAR 
GENETICS R227, R228 (2010); Chandra Shekhar Pareek et al., Sequencing Technologies and 
Genome Sequencing, 52 J. APPLIED GENETICS 413, 419 (2011). 
 107 Daniel Branton et al., The Potential and Challenges of Nanopore Sequencing, 26 NATURE 
BIOTECHNOLOGY 1146, 1146 (2008). This is in contrast to the prior forms of sequencing at each 
level of generality: large scale, which is the jigsaw-like assembly of smaller sequences; and 
small-scale, where the sequencing experiment itself does not involve sequential reading of 
bases, but the rather complex Sanger process. There, many, many copies of the same fragment 
are made with the addition of a small portion of labeled bases (labeled differently for A,C,G, 
and T) that cause termination—by sorting the resulting copies based on length, the sequencer 
can “read” the last base in each slightly longer fragment, and thereby read the sequence of the 
original source. 
 108 Id. at 1148–49; Winston Timp et al., Nanopore Sequencing: Electrical Measurements of the 
Code of Life, 9 IEEE TRANSACTIONS NANOTECHNOLOGY 281, 283 (2010). 
 109 See supra note 108. 
 110 Branton et al., supra note 107, at 1146. 
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hole in a silicon or grapheme barrier,111 or some other manifestation. 
The barrier with the nanopore is placed in a conductive fluid, and volt-
age is applied across the barrier.112 The movement of ions in the fluid 
through the pore creates a very small current, which can be detected.113 
When a strand of DNA is threaded through the hole, the size of the pore 
means that only one base can pass through at a time (the strand cannot 
be doubled-up, for instance)—this ensures that the bases are encoun-
tered in sequence.114 As each base passes through the pore, it blocks the 
pore to a certain characteristic degree, which can be read as small fluc-
tuations in the current.115 This technique, unlike traditional sequencing, 
can be performed on a single molecule of DNA—indeed, it can only be 
performed on a single molecule at a time.116 
Perhaps more importantly, unlike traditional sequencing, in which 
long DNA strands are broken down into much smaller fragments, in 
nanopore sequencing no such fragmentation is necessary.117 Theoreti-
cally, an entire chromosome could be sequentially read from end to end 
in a seamless process.118 Alternatively, in some versions of the tech-
nique, the DNA strand is initially fed into the apparatus in one strand, 
but immediately before passing through the pore and being read, each 
nucleotide is cut off from the remaining strand and passes through the 
pore as a nucleotide unconnected to the strand; this reduces the poten-
tial interference from adjacent bases which can affect the current despite 
not actually being in the center of the pore.119 
For this sequencing technique to infringe the composition claims 
of gene patents, as before, it would have to create or use an isolated nu-
cleic acid which is specified by one of the three prototypical forms of 
sequence claims. It seems highly unlikely that either form of nanopore 
sequencing would infringe. In the non-cleaving variation, the DNA 
molecule which is used for sequencing is indeed isolated from other 
cellular components, but certainly not from other genetic material in the 
chromosome—the strands being sequenced are by design extremely 
long, and can be as long as an entire chromosome. This is clearly outside 
the broadest feasible definition of “isolated”—so even if the strand does 
include the specified sequence, which it would, there is no infringement. 
In the cleaving variation, on the other hand, the DNA exists in one of 
two forms—either the single long strand, which has just been shown not 
 
 111 Timp et al., supra note 108, at 286. 
 112 Id. at 283–84. 
 113 Id. at 283. 
 114 Id. at 283–84. 
 115 Id. at 283–85. 
 116 Id. at 284. 
 117 Id. at 283. 
 118 Id. at 283, 292. 
 119 See, e.g., Branton et al., supra note 107, at 1149. 
PRICE.33-4 4/2/2012 3:56 PM 
1626 C ARD O Z O  L A W R E V IE W  [Vol. 33:4 
to infringe, or the single nucleotides after cleavage, which are actually 
“used” in the sequencing step itself. Those single nucleotides clearly do 
not fall into any of the sequence-specifying aspects of the composition 
claims. 
Overall, with respect to the composition-of-matter claims in gene 
patents, the infringement status of WGS depends on the specific se-
quencing technique used and even the operational parameters of that 
technique. The two traditional methods of sequencing likely infringe a 
small number of whole-gene claims, but can probably be modified to 
avoid infringement of most of those claims. Either of the traditional 
techniques almost certainly infringes many short-sequence gene claims, 
but those claims are very unlikely to withstand validity analysis. Finally, 
nanopore sequencing, though still a nascent technology, does not ap-
pear to infringe any of the composition claims of mainstream gene pa-
tents. 
 
III.     DRAWING MEDICAL CONCLUSIONS AND COMMUNICATING WITH THE 
PATIENT LIKELY INFRINGES CURRENT PATENTS, BUT THOSE  
CLAIMS ARE OF QUESTIONABLE VALIDITY UNDER  
ASSOCIATION FOR MOLECULAR PATHOLOGY 
 
Whether whole-genome scanning infringes gene patents’ composi-
tion-of-matter claims or not, it may also infringe the diagnosis-based 
methods claims present in many of those patents. Unlike gene composi-
tion claims, which are generally valid, however, genetic testing diagnosis 
methods claims are on far shakier validity footing; one broad class is 
certainly invalid under current law. Therefore, this Part will briefly 
(though not exhaustively) analyze the serious validity concerns in diag-
nosis methods patents. Then, assuming validity of at least some forms of 
method claims, it will indicate the ways in which WGS likely violates 
those claims. 
As described in more detail above,120 these method claims can in-
clude: (1) determining the gene sequence in the patient; (2) comparing 
that gene sequence to the wild-type sequence (or identified mutations) 
in the patent; and (3) using that similarity or difference to diagnose the 
medical condition linked to mutations in that gene. So, for instance, to 
practice the method claimed in Duke’s ApoE patent, one would se-
quence the patient’s ApoE gene, compare those with the wild-type se-
quence in Duke’s patent, and then draw a conclusion of mutation from 
any differences. Presumably the next step is to inform the patient; how-
 
 120 See supra Part I.B. 
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ever, any attempts to improve patentability by including this in the 
claimed method are likely to be unsuccessful.121 
The analysis of diagnostic methods claims is somewhat more com-
plex due to the larger variation in precise claim-drafting terms. The 
claims can involve the step of actually determining the sequence of pres-
ence of a gene variant (as in the ApoE patent), or can assume that the 
sequence has already been determined (as in the BRCA1 patent). They 
can also optionally involve a step of making the actual diagnosis, or can 
just leave that as a “wherein” clause attached to the comparison. For the 
purposes of this analysis, these method claims can be divided into essen-
tially two classes. In the first, the methods claim includes only compari-
son and diagnosis steps—which can be classified as mental processes. In 
the second type of claim, the method also explicitly includes a step of 
determining the sequence of the gene at issue. 
The first type of methods claim, a comparison-only method, exem-
plified by the BRCA1 patent, has been held by the Federal Circuit to be 
unpatentable under section 101.122 In a literal interpretation of the 
claims, looking at and comparing two pieces of paper with sequences, 
one from a patient and one from a reference sequence, would infringe 
the patent. In AMP II, Myriad argued that the comparison of genetic 
sequences implicitly required a first step of sequencing the DNA.123 
Therefore, it argued, the claim was not for unpatentable “abstract men-
tal processes,” but for an integrated method which satisfied the ma-
chine-or-transformation test, which under Bilski provides a “useful and 
important clue” for patentable subject matter.124 The Federal Circuit 
rejected this argument; sequence comparison claims that do not explic-
itly claim transformative steps are unpatentable subject material under 
section 101 as abstract mental processes.125 
The second type of methods claim actually does involve a trans-
formation, as long as the determination of genetic sequence is found to 
be transformative. Prometheus strongly suggests that it will be.126 In 
AMP II, the Federal Circuit distinguished the Myriad claims from those 
in Prometheus: “Myriad’s claims, in contrast, do not include the step of 
‘determining’ the sequence of BRCA genes by, e.g., isolating the genes 
from a blood sample and sequencing them, or any other necessarily 
 
 121 See King Pharm., Inc. v. Eon Labs, Inc., 616 F.3d 1267, 1278 (Fed. Cir. 2010). 
 122 AMP II, 653 F.3d 1329, 1355 (Fed. Cir. 2011). 
 123 Id. at 1355–56. 
 124 Bilski v. Kappos, 130 S. Ct. 3218, 3226–27 (2010). 
 125 AMP II, 653 F.3d at 1356–57. Myriad also argued that the limitation to genetic testing for 
its specific sequences made the claim patentable. However, the limitations to a specific field or 
application cannot make mental processes patentable. Id. at 1356 (citing Bilski, 130 S. Ct. at 
3230). 
 126 Prometheus Labs. v. Mayo Collaborative Servs., 628 F.3d 1347, 1355–58 (Fed. Cir. 2010). 
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transformative step.”127 This language strongly implies that method 
claims which do explicitly include a sequence-determining step are val-
id, at least in a patentable subject matter analysis under section 101. 
Despite the likelihood of invalidity for at least some claims, if the 
diagnostic methods claims are broadly assumed to be valid, does WGS 
infringe? Obviously, the step of actually generating the sequence itself 
cannot infringe, since merely creating the sequence does not involve any 
type of comparison. However, the purpose of WGS is not merely to 
develop a three billion–letter piece of personal information; it is to have 
a sequence that can be used to determine useful information about the 
sequenced person, whether medical (a disease propensity, more com-
monly) or personal (ancestry, athletic propensity, or whatever else is 
linked to a particular gene). 
Since comparison-only claims have been held invalid, the in-
fringement analysis need only be performed for those method claims 
which include the transformative/determination step of actually deter-
mining the sequence.128 For the determination/comparison claims, the 
crucial issue is whether any single actor actually performs all of the steps 
of the method, which is required for infringement of a method claim.129 
 
 127 AMP II, 653 F.3d at 1357. 
 128 The methods claims which involve only the comparative step are very easy to infringe 
since they involve essentially the most meaningful steps in the area of genetic sequencing. The 
goal of genetic sequencing is to determine the physical/medical/informational outcome by 
measuring the difference between a sequenced gene and the wild-type version (and any panel of 
known mutations)—this essential step is covered by the comparison-only claims. Therefore, a 
gene-sequencing company that reported the patient’s sequence and included data on which 
sequence characteristics were mutations would be infringing the claim; a doctor using the 
sequence to diagnose would be infringing; and even a patient who was given the unannotated 
sequence and the set of known mutations and wild-type variations would infringe by making 
the comparison himself or herself. It is true that a genetic testing company would likely be loath 
to sue the end users for making any comparison themselves—but, practically speaking, the 
universe of individuals who would comfortably self-diagnose a genetic disorder without medi-
cal intervention is likely small. More importantly, the promise of individualized medicine, and 
of integration with the medical system, demands that any sequencing comparison actually be 
made within the context of medical actors; therefore, comparison-only method claims almost 
certainly would be infringed by suit-vulnerable actors in a WGS paradigm. 
 129 Current law requires that a single actor either perform all steps or control and direct the 
performance of whatever steps it does not itself perform. Muniauction, Inc. v. Thomson Corp., 
532 F.3d 1318, 1328–30 (Fed. Cir. 2008); BMC Res., Inc. v. Paymentech, L.P., 498 F.3d 1373, 
1378–79 (Fed. Cir. 2007). This requirement was upheld by a three-judge panel of the Federal 
Circuit in Akamai Techs., Inc. v. Limelight Networks, 629 F.3d 1311, 1318–21 (Fed. Cir. 2010), 
vacated sub nom. Akamai Techs., Inc. v. Mass. Inst. of Tech., 419 F. App’x 989 (2011) (granting 
rehearing en banc). The en banc Federal Circuit has requested briefs on the question, “If sepa-
rate entities each perform separate steps of a method claim, under what circumstances would 
that claim be directly infringed and to what extent would each of the parties be liable?” Id. at 
989. How the Federal Circuit will answer this question can only be speculated; however, unless 
the Federal Circuit reinterprets joint infringement in an extraordinarily sweeping fashion, 
infringement of determination/comparison claims will still be relatively easy to avoid. Even if 
agency, control, or determination is no longer a requirement for multi-party infringement of a 
method, some link or coordination requirement seems inevitable. In that case, infringement of 
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It is likely that a genetic sequencing company would prefer to make 
available not only the sequencing results themselves but also some level 
of interpretation of those results. However, since such a practice would 
open the company to potential liability for infringing determina-
tion/comparison claims,130 it might well choose to make only the unan-
notated sequence available to a patient or his physician, who would then 
compare the personal sequence to a database of wild-type and known 
mutant sequences. This procedure would separate the two steps of the 
method, and no single individual would then be using the entire meth-
od, thus avoiding infringement. 
Overall, it seems that diagnostic method claims that involve only a 
comparative step are easy for a company, doctor, or patient to infringe, 
but are highly vulnerable to validity attacks based on their resemblance 
to purely mental processes or abstract ideas. Method claims that involve 
both sequence determination and comparison steps, on the other hand, 
fall more cleanly under the sufficient-but-not-necessary machine-or-
transformation test, but are relatively easy to circumvent by having dif-
ferent legal actors perform the sequence-determination and compari-
son/diagnosis steps, as is likely to be the norm in an era of widespread 
WGS, where the genome need only be sequenced once, but potentially 





To a certain extent, the precise contours of infringement of the 
thousands of extant gene patents tell only part of the story. Certain se-
quencing techniques are likely to infringe many composition-of-matter 
claims for isolated genes, although they can potentially work around 
that infringement by changing the parameters of traditional techniques 
or by using nanopore methods, which appear more suitable for wide-
spread WGS in any case. The diagnostic methods claims are likely either 
invalid or avoidable. However, a crucial aspect of the infringement land-
 
a determination/comparison claim can be avoided by the widespread availability of WGS itself. 
Once WGS to determine a patient’s genomic sequence becomes a normal background step—a 
one-time determination like blood-typing—then future sequence comparisons or analyses are 
uncoupled from the determination step, and a determination/comparison claim would lack the 
necessary coordination for multi-party infringement. 
 130 A practice of actually providing diagnoses, rather than just information, might also run 
afoul of corporate-practice-of-medicine laws, unlicensed practice of medicine across state lines, 
and other various potential sources of liability, so that sequencing companies might for other 
reasons prefer to separate the diagnosis/interpretation functions from the sequence-providing 
functions—as, indeed, some sequencing companies already do. See, e.g., Terms of Service, 
23ANDME, https://www.23andme.com/about/tos (last visited Feb. 15, 2012). 
PRICE.33-4 4/2/2012 3:56 PM 
1630 C ARD O Z O  L A W R E V IE W  [Vol. 33:4 
scape is that at least some uncertainty remains, which may itself have 
negative impacts. This Article has attempted to construct general anal-
yses using the typical language of gene patents, and apply that language 
to generally used sequencing techniques. It is difficult to impossible, 
however, to rule out the possibility that among the thousands of extant 
human gene patents, there may be some which could be harder or un-
feasible to work around. This uncertainty casts a pall of indefinite 
strength over the enterprise of WGS and personalized medicine; even if 
in actuality no or almost no valid patents are actually infringed, the 
looming threat of infringement lawsuits, and the costs of determining 
patent invalidity may deter some market actors.131 
Those who argue for broad policy options with respect to diagnos-
tic genetic testing do so based on a perception that WGS infringes many 
gene patents. Whether it does so or not—and whether the techniques 
can be or are modified to avoid infringement—policy options to shield 
diagnostic testing from infringement lawsuits are likely to smooth the 
way for personalized medicine. These policy options have been de-
scribed in greater depth elsewhere, but include a research exemption for 
diagnostic testing (which would allow the improvement of tests, but not 
solve the issue of WGS), a generalized exemption from infringement for 
all diagnostic use (which would upset companies like Myriad but open 
wide the path for personalized medicine), and mandatory gene-patent 
clearinghouses, which could eliminate the problem of holdouts and 
provide for at least some revenue sharing. One final approach is the 
elimination of gene patents altogether, either through statutory action 
(which seems unlikely) or through court action through the likely vehi-
cle of the Association for Molecular Pathology case. Needless to say, the 
elimination of gene patents would obviously allow WGS and personal-
ized medicine without fear of infringement. 
An additional policy consideration is the availability of infringing 
options abroad. Sequencing and sequence comparison could easily be 
performed abroad without infringing U.S. patents; the consumer-
relevant information—that is, identification of allelic variations and 
drug susceptibility profiles—does not infringe gene patents. Given the 
ease of overseas sequencing and comparing, policy arguments could be 
made that attempting to strengthen gene patent protection for diagnos-
tic testing is likely to do more than drive those tasks, jobs, and dollars 
overseas. 
 
 131 See, e.g., AMP II, 653 F.3d at 1355 (Bryson, J., concurring in part and dissenting in part) 
(“Even if many of those patents include claims that are invalid for anticipation or obviousness, 
the costs involved in determining the scope of all of those patents could be prohibitive.”) (citing 
SACGHS REPORT, supra note 17, at 51–52; and Rebecca S. Eisenberg, Noncompliance, 
Nonenforcement, Nonproblem? Rethinking the Anticommons in Biomedical Research, 45 HOUS. 
L. REV. 1059, 1076–80 (2008)). 
PRICE.33-4 4/2/2012 3:56 PM 
2012] U N B LO C KE D  FU T U R E  1631 
Overall, it seems that infringement of intellectual property is far 
less of a systematic and pervasive barrier to WGS and personalized med-
icine than is generally assumed. Isolated gene claims may be avoidable 
by slightly changing the old techniques or using the new nanopore 
technique, which shows tremendous promise, despite its being some 
distance from commercial use (a characteristic of all WGS possibilities). 
And determination/diagnosis claims seem either invalid or avoidable as 
well. Perhaps policy changes would make the landscape a less risky one 
for innovators going forward, but it appears that, even with the status 
quo, WGS may be able, cautiously and mindfully, to proceed. 
